earnings
confidence high
sentiment positive
materiality 0.75
Sana Biotechnology Q2 loss $0.39/sh (GAAP); positive type 1 diabetes cell therapy data; raises $105M
Sana Biotechnology, Inc.
2025-Q2 EPS
reported -$0.60
vs consensus -$0.21
▼ miss
(-184.4%)
- Net loss $93.8M ($0.39/sh GAAP); non-GAAP net loss $38.9M ($0.16/sh) vs $74.2M ($0.32/sh) year ago.
- Cash, cash equivalents & securities $72.7M at June 30; pro forma $177.2M including $105M raised in July/August 2025.
- Six-month data show transplanted HIP-edited islet cells survive & function (C-peptide+) without immunosuppression; NEJM published 12-week results.
- Expect to file IND for SC451 (iPSC-derived islet cell therapy) as early as 2026; FDA INTERACT meeting supports GMP master cell bank.
- Enrolling GLEAM (SC291 in autoimmune) & VIVID (SC262 in B-cell malignancies); data expected 2025; IND for SG299 in vivo CAR T as early as 2026.